MX358474B - Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. - Google Patents
Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.Info
- Publication number
- MX358474B MX358474B MX2014012306A MX2014012306A MX358474B MX 358474 B MX358474 B MX 358474B MX 2014012306 A MX2014012306 A MX 2014012306A MX 2014012306 A MX2014012306 A MX 2014012306A MX 358474 B MX358474 B MX 358474B
- Authority
- MX
- Mexico
- Prior art keywords
- prognosis
- parkinson
- alzheimer
- diseases
- monitoring
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
- G01N2333/926—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha -1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a un método de diagnóstico in vitro de la enfermedad de Alzheimer, caracterizado porque comprende los pasos de: probar una muestra de saliva para niveles de un grupo de biomarcadores que consiste de IGF-I, IGF-II, Aß-40, Aß-42, alfa amilasa, IL-1 beta y TNF-alfa; y determinar que la muestra de saliva es positiva para la enfermedad de Alzheimer si los niveles del grupo de biomarcadores pasan todos los criterios en un grupo de criterios de prueba que consiste de; nivel de Aß-40 inferior a un nivel de referencia de Aß-40, nivel de TNF. Alfa superior a un nivel de referencia de TNF-alfa, nivel de IL-1 beta superior a un nivel de referencia de IL-1 beta, nivel de Aß-42 superior a un nivel de referencia de Aß-42, nivel de IGF-I inferior a un nivel de referencia de IGF-I, nivel de IGF-II inferior a un nivel de referencia de IG-II, y nivel de alfa-amilasa superior a un nivel de referencia de alfa-amilasa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1138DE2012 | 2012-04-13 | ||
PCT/IB2013/001407 WO2013153461A2 (en) | 2012-04-13 | 2013-04-12 | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014012306A MX2014012306A (es) | 2015-05-07 |
MX358474B true MX358474B (es) | 2018-08-21 |
Family
ID=48998640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014012306A MX358474B (es) | 2012-04-13 | 2013-04-12 | Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP3255435A1 (es) |
AU (2) | AU2013246621A1 (es) |
CA (1) | CA2877975C (es) |
MX (1) | MX358474B (es) |
WO (1) | WO2013153461A2 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11112405B1 (en) | 2020-05-18 | 2021-09-07 | Baseline Global, Inc. | Assay device, system, method, and kit |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3067699A1 (en) | 2015-03-11 | 2016-09-14 | Neuron Bio, S.A. | Method for diagnosing alzheimer's disease |
US20180107783A1 (en) * | 2015-05-28 | 2018-04-19 | Immunexpress Pty Ltd | Validating biomarker measurement |
PT3171174T (pt) * | 2015-11-20 | 2018-01-12 | Geroa Diagnostics S L | Lactoferrina para utilização no diagnóstico ou no prognóstico da doença de alzheimer |
EP3491383A4 (en) * | 2016-07-28 | 2019-11-27 | Aurin Biotech Inc. | ABETA42 CONCENTRATIONS IN THE STORE AS PROGNOSTIC INDICATORS FOR MORBUS ALZHEIMER |
EP3312611B1 (en) | 2016-10-21 | 2020-02-26 | Dr. Power Stem Biomedical Research Inc., Ltd. | Method for diagnosis of alzheimer's disease |
EP3376230A1 (en) | 2017-03-13 | 2018-09-19 | Biocross, S.L. | Identification of signatures for neurodegeneration diseases diagnoses |
JP7339953B2 (ja) | 2018-02-14 | 2023-09-06 | サリグノスティクス リミテッド | 分析対象物を検出するための方法及び装置 |
CN111781376A (zh) * | 2020-07-08 | 2020-10-16 | 东南大学深圳研究院 | 一种阿尔茨海默病生物标志物的快速检测方法 |
WO2022087694A1 (pt) * | 2020-10-26 | 2022-05-05 | Frans Eduardo | Diagnóstico de alzheimer vía saliva utilizando o método lateral flow assay |
EP4237857A1 (en) * | 2020-10-30 | 2023-09-06 | Baseline Global, Inc. | Methods, systems, and kits for prediction, detection, monitoring, and treatment of alzheimer's disease |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4728605A (en) | 1984-07-31 | 1988-03-01 | Fudenberg Herman H | Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same |
EP0625212B1 (en) | 1992-10-13 | 2004-03-24 | Duke University | Methods of detecting alzheimer's disease |
EP0760098A4 (en) | 1994-06-09 | 1997-07-16 | Univ Bar Ilan | DIAGNOSIS OF THE PATHOLOGICAL PHASE OF ALZHEIMER'S DISEASE BASED ON CYONKIN SECRETIONS BY MONONUCLEAR CELLS |
US5686269A (en) | 1994-07-28 | 1997-11-11 | The Mclean Hospital Corporation | Method of diagnosing Alzheimer's disease by detecting the level of cathepsin D in cerebrospinal fluid |
US6114133A (en) | 1994-11-14 | 2000-09-05 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) |
AUPO943297A0 (en) | 1997-09-24 | 1997-10-16 | University Of Melbourne, The | Diagnostic test for alzheimer's disease |
US6358681B2 (en) | 1998-10-30 | 2002-03-19 | The Trustees Of The University Of Pennsylvania | Diagnostic methods for alzheimer's disease by detection of multiple mRNAs |
CA2269432C (en) | 1998-06-01 | 2002-04-02 | Hyman M. Schipper | Ho-1 as a diagnostic and prognostic test for dementing diseases |
US6465195B2 (en) | 1999-12-30 | 2002-10-15 | Washington University | Predictive diagnostic for Alzheimer's disease |
US6495335B2 (en) | 2000-12-07 | 2002-12-17 | Mario Chojkier | Compositions and methods for diagnosing alzheimer's disease |
US6475161B2 (en) | 2001-03-29 | 2002-11-05 | The Mclean Hospital Corporation | Methods for diagnosing Alzheimer's disease and other forms of dementia |
US6451547B1 (en) | 2001-04-25 | 2002-09-17 | Syn X Pharma | Process for differential diagnosis of Alzheimer's dementia and device therefor |
US7344853B2 (en) | 2003-01-27 | 2008-03-18 | Baylor College Of Medicine | Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin |
WO2005047484A2 (en) | 2003-11-07 | 2005-05-26 | Ciphergen Biosystems, Inc. | Biomarkers for alzheimer's disease |
CA2546461A1 (en) | 2003-11-19 | 2005-06-09 | Satoris, Inc. | Methods for diagnosis, stratification, and monitoring of alzheimer`s disease |
US7927548B2 (en) | 2005-01-27 | 2011-04-19 | Bamburgh Marsh Llc | Specimen sample collection device and test system |
WO2005072398A2 (en) | 2004-01-28 | 2005-08-11 | Bamburgh Marrsh Llc | Specimen sample collection device and test system |
GB0421639D0 (en) | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
US7833513B2 (en) | 2004-12-03 | 2010-11-16 | Rhode Island Hospital | Treatment of Alzheimer's Disease |
US7993868B2 (en) | 2005-04-19 | 2011-08-09 | Vermillion, Inc. | Saposin D and FAM3C are biomarkers for alzheimer's disease |
US20090263829A1 (en) | 2006-03-14 | 2009-10-22 | Washington University In St. Louis | Alzheimer's disease biomarkers and methods of use |
US7851172B2 (en) | 2006-07-25 | 2010-12-14 | University Of Kentucky Research Foundation | Biomarkers of mild cognitive impairment and alzheimer's disease |
WO2008100596A2 (en) | 2007-02-15 | 2008-08-21 | Burnham Institute For Medical Research | Biomarkers of neurodegenerative disease |
US20090061457A1 (en) | 2007-09-05 | 2009-03-05 | Power3 Medical Products, Inc. | Apolipoprotein E3 protein as a biomarker of Parkinson's disease |
US20100167937A1 (en) | 2008-07-08 | 2010-07-01 | Power3 Medical Products, Inc. | Multiple forms of Alzheimer's disease based on differences in concentrations of protein biomarkers in blood serum |
-
2013
- 2013-04-12 CA CA2877975A patent/CA2877975C/en active Active
- 2013-04-12 MX MX2014012306A patent/MX358474B/es active IP Right Grant
- 2013-04-12 EP EP17178876.3A patent/EP3255435A1/en not_active Withdrawn
- 2013-04-12 WO PCT/IB2013/001407 patent/WO2013153461A2/en active Application Filing
- 2013-04-12 AU AU2013246621A patent/AU2013246621A1/en not_active Abandoned
- 2013-04-12 EP EP13750374.4A patent/EP2836844B1/en not_active Not-in-force
-
2019
- 2019-01-15 AU AU2019200241A patent/AU2019200241A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11112405B1 (en) | 2020-05-18 | 2021-09-07 | Baseline Global, Inc. | Assay device, system, method, and kit |
Also Published As
Publication number | Publication date |
---|---|
MX2014012306A (es) | 2015-05-07 |
AU2019200241A1 (en) | 2019-01-31 |
WO2013153461A2 (en) | 2013-10-17 |
WO2013153461A3 (en) | 2014-05-15 |
AU2013246621A1 (en) | 2014-11-27 |
EP2836844A2 (en) | 2015-02-18 |
EP2836844B1 (en) | 2017-08-16 |
CA2877975C (en) | 2021-09-21 |
CA2877975A1 (en) | 2013-10-17 |
EP3255435A1 (en) | 2017-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX358474B (es) | Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. | |
EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
MX2013000917A (es) | Metodos para detectar las enfermedades o condiciones usando celulas fagociticas. | |
WO2015061634A3 (en) | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders | |
WO2014160499A3 (en) | Methods and compositions for detecting pancreatic cancer | |
AU2015318823A1 (en) | Methods for diagnosis, prognosis and monitoring of breast cancer and reagents therefor | |
NZ606725A (en) | Methods for predicting anti-cancer response | |
MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
WO2013066369A3 (en) | Methods for detecting graft-versus-host disease | |
EP3176268A4 (en) | Novel biomarker for predicting sensitivity to egfr-targeting agent, and use thereof | |
HK1206423A1 (en) | Oligomeric in the diagnosis, prognosis, nd monitoring of alzheimers disease | |
PH12014502436A1 (en) | In vitro method for the diagnosis and surveillance of cancer | |
WO2012078623A3 (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
MX2023005452A (es) | Deteccion de beta amiloide por espectrometria de masas. | |
EP2723866A4 (en) | METHOD FOR THE PROGNOSIS AND / OR DIAGNOSIS OF NEURODEEGENERATIVE DISEASES, METHOD FOR IDENTIFYING COMPOUND CANDIDATES AND COMPOUNDS FOR THE TREATMENT OF NEURODEGENATIVE DISEASES | |
EP2888370A4 (en) | DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES | |
EP4202441A3 (en) | Gene expression profile in macrophages for the diagnosis of cancer | |
MX2016001719A (es) | Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
EP3098311A4 (en) | Method for measuring modified nucleobase using guide probe, and kit therefor | |
MX363679B (es) | Metodo para diagnosticar cancer. | |
EP3088895A4 (en) | Method for analyzing information for diagnosis and kit therefor | |
EP3045916A4 (en) | Kit and method for diagnosis, prognosis or monitoring of liver disease through measurement of amount of ast | |
IN2014DN08312A (es) | ||
EP3088896A4 (en) | Method for analyzing information for diagnosis and kit therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |